We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Determination of Predictive Value of Echography Doppler Abnormalities (CAVECCAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00714909
Recruitment Status : Unknown
Verified February 2011 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Recruiting
First Posted : July 14, 2008
Last Update Posted : February 23, 2011
Information provided by:

Study Description
Brief Summary:
In order to avoid to use a traumatic and iatrogenic examen (phlebography), the purpose of the study is to validate echography doppler in the diagnosis of asymptomatic related catheter related thrombosis.

Condition or disease
Breast Cancer Upper Extremity Deep Vein Thrombosis, Secondary

Detailed Description:

Phlebography is the gold standard for the diagnosis of asymptomatic catheter related thrombosis but can not be performed in about 15% of patients because of arm swelling and lack of superficial veins.

Echography doppler is an easy, cheap and atraumatic way to make the diagnosis of deep vein thrombosis. The value of echography doppler has been proven for the diagnosis of symptomatic deep venous thrombosis of lower and upper limbs and for the diagnosis of proximal asymptomatic lower limbs.

To validate the echography doppler we intend to correlate asymptomatic findings to the occurrence symptomatic related catheter related thrombosis.

Patients with localized breast cancer treated with chemotherapy will be enrolled in the study. An echography doppler will be performed on day 8, 30 and 90 after catheter insertion. Findings in asymptomatic patients (thrombus visualisation, lack of vein compressibility, variation of physiologic vein blood flow) will thereafter be correlated with the presence or absence of clinical signs of catheter related thrombosis.

In order to assess if they are risk factors for catheter related thrombosis, we will determine the level D-Dimer, microparticles and the results of generation thrombin tests before and 2 days after catheter insertion.

Study Design

Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: CAVECCAS Value of Risk Factors for Symptomatic Catheter Related Thrombosis in Patients With Breast Cancer Treated With Adjuvant Chemotherapy
Study Start Date : November 2008
Estimated Primary Completion Date : November 2011
Estimated Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. Symptomatic catheter related thrombosis, as confirmed by echography doppler, phlebography or angiography scan [ Time Frame: within 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All consecutive patients treated receiving adjuvant chemotherapy for localized breast cancer in the participating centers

Inclusion Criteria:

  • women over 18
  • histologically proven breast cancer
  • localized breast cancer without metastasis
  • adjuvant or neo adjuvant chemotherapy
  • insertion of central catheter with port for chemotherapy
  • central catheter for more than three months
  • inform consent
  • follow up for three months

Exclusion Criteria:

  • ongoing anticoagulant therapy
  • previous central catheter
  • femoral catheter
  • double lumen catheter
  • central catheter without port
  • platelets < 80G/L, TQ < 50%, fibrinogen < 1 g/L
  • creatinin > 175mole/L
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00714909

Contact: Philippe M Debourdeau, MD +33 1 4249 9768 onco.debourdeau@yahoo.fr

Saint-Louis Hospital Recruiting
Paris, France, 75010
Contact: Philippe M Debourdeau, MD    +33 1 4249 9768    onco.debourdeau@yahoo.fr   
Principal Investigator: Philippe M Debourdeau, MD         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Philippe M Debourdeau, MD Saint-Louis Hospital, Paris, France
More Information

Responsible Party: Isabelle Brindel, Department Clinical Research of developpement
ClinicalTrials.gov Identifier: NCT00714909     History of Changes
Other Study ID Numbers: K070104
First Posted: July 14, 2008    Key Record Dates
Last Update Posted: February 23, 2011
Last Verified: February 2011

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Breast cancer
Catheter related thrombosis
Echography doppler
Risk factors

Additional relevant MeSH terms:
Breast Neoplasms
Venous Thrombosis
Upper Extremity Deep Vein Thrombosis
Neoplasms by Site
Breast Diseases
Skin Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases